WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2016/083336    International Application No.:    PCT/EP2015/077438
Publication Date: 02.06.2016 International Filing Date: 24.11.2015
A61K 9/127 (2006.01), A61K 47/48 (2006.01), A61K 9/14 (2006.01), A61K 9/51 (2006.01), A61K 31/704 (2006.01)
Applicants: NANOBIOTIX [FR/FR]; 60 rue de Wattignies 75012 Paris (FR)
Inventors: MEYRE, Marie-Edith; (FR).
POTTIER, Agnès; (FR).
LEVY, Laurent; (FR)
Agent: CABINET BECKER ET ASSOCIES; 25, rue Louis le Grand 75002 Paris (FR)
Priority Data:
14306873.2 25.11.2014 EP
Abstract: front page image
(EN)The present invention relates to a pharmaceutical composition comprising the combination of (i) at least one biocompatible nanoparticle and of (ii) at least one pharmaceutical compound, to be administered to a subject in need of such a pharmaceutical compound, wherein the nanoparticle potentiates the pharmaceutical compound efficiency. The longest dimension of the biocompatible nanoparticle is typically between about 4 and about 500 nm, its absolute surface charge value is of at least 10 mV (|10 mV|), and its Young modulus is less than 100 kPa. The invention also relates to such a composition for use for administering the pharmaceutical compound in a subject in need thereof, wherein the at least one nanoparticle and the at least one pharmaceutical compound are to be administered in the subject between more than 5 minutes and about 72 hours one from each other.
(FR)La présente invention concerne une composition pharmaceutique comprenant la combinaison de (i) une nanoparticule biocompatible et de (ii) au moins un composé pharmaceutique, à administrer à un sujet ayant besoin de ce composé pharmaceutique, la nanoparticule potentialisant l'efficacité du composé pharmaceutique. La dimension la plus longue de la nanoparticule biocompatible est généralement comprise entre environ 4 et environ 500 nm, sa valeur absolue de charge de surface est d'au moins 10 mV (|10 mV|) et son module de Young est inférieur à 100 kPa. L'invention concerne aussi une telle composition destinée à être utilisée pour l'administration du composé pharmaceutique à un sujet le nécessitant, la ou les nanoparticules biocompatibles et le ou les composés pharmaceutiques devant être administrés au sujet avec un intervalle entre eux compris entre plus de 5 minutes et environ 72 heures.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)